CRISPR-Cas-Based Platform for Single-Step Quantification of Monoclonal Antibodies at Point-of-Care
Year: 2026
Type: article
Abstract: We report a streamlined, cost-effective point-of-care platform for the quantitative detection of monoclonal antibodies for therapeutic drug monitoring, addressing the limitations of bulky, complex, and expensive instrumentation required for standard analytical techniques. In contrast to conventional immunoassays that rely on primary/secondary antibodies for quantification, our method leverages a DNA circuit for the recognition of the target monoclonal antibody coupled with CRISPR-Cas12a signal amplification. This assay is integrated into a microfluidic chip that enables a single-step workflow, eliminating the multiple incubations and reagent addition steps typical of laboratory methods. The platform demonstrates quantitative detection of a model anti-hemagglutinin antibody within a 60-min sample-to-answer timeframe, in the nanomolar range, with a chip manufacturing cost below 1€ and reagent stability confirmed at -20 °C for over one month. This proof-of-concept illustrates the potential of simplified CRISPR-based assays for decentralized rapid protein quantification in clinical settings.
Source: ACS Sensors
Authors: Stefano Del Giovane, Davide Migliorelli, Samantha Paoletti, Neda Bagheri, Hatice Altug, Loïc Burr
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Awards: Twisted nanophotonic technology for integrated chiroptical sensing of drugs on a chip, NANOTECHNOLOGY-ENABLED DETECTION OF CLINICALLY RELEVANT ANTIBODIES FOR EARLY CANCER DIAGNOSIS AND IMMUNOTHERAPY MONITORING, From understanding spatiotemporal biology of lymph node metastases to personalized minimally-invasive treatment strategies for head and neck cancers, G7317980702, Twisted nanophotonic technology for integrated chiroptical sensing of drugs on a chip
OpenAlex ID: W7166732294